Guide for an injection device

US10709849B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10709849-B2
Application numberUS-201414897400-A
CountryUS
Kind codeB2
Filing dateJun 11, 2014
Priority dateJun 11, 2013
Publication dateJul 14, 2020
Grant dateJul 14, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

There is provided a guide 200 for contacting an injection device 110 with a user; the guide 200 having a first end 210 adapted to engage a housing 112 of the injection device 110 and a second end 220 adapted to engage the surface of a user's skin, wherein the guide 200 permits movement of the housing 112 towards the user's skin.

First claim

Opening claim text (preview).

The invention claimed is: 1. A guide for contacting an injection device with a user, the guide comprising: a first component including a first end adapted to engage a housing of the injection device, the first component including at least one ratchet tooth; a second component including a second end adapted to engage a surface of the user's skin, wherein the second component is movable with respect to the first component, and wherein the second component comprises an inner surface including a plurality of ratchet teeth disposed in series that engage the at least one ratchet tooth on the first component such that the housing moves towards the user's skin incrementally. 2. The guide of claim 1 , wherein the first end is open. 3. The guide of claim 1 or claim 2 , wherein the second end is open. 4. The guide of claim 1 , wherein the guide is cylindrical. 5. The guide of claim 1 , wherein the guide is formed as a frame. 6. The guide of claim 1 , wherein the guide is formed with a continuous external surface. 7. The guide of claim 1 , wherein the guide comprises at least one stabilising element at the second end which is adapted to project from the guide and stabilise the guide on the skin. 8. The guide of claim 7 , wherein the guide comprises three stabilising elements at the second end. 9. A kit comprising the guide of claim 1 and an automatic injection device having a housing. 10. The kit of claim 9 , wherein the housing has a distal end and the first end of the guide is adapted to engage the housing at the distal end. 11. The kit of claim 9 , wherein the housing has a first diameter and the first end is dimensioned to surround the first diameter. 12. The kit of claim 11 , wherein a portion of the housing has a second diameter which is larger than the first diameter and the first end is dimensioned to engage the portion of the housing having a second diameter. 13. The kit of claim 12 , wherein the second diameter portion comprises a ridge. 14. The kit of claim 9 , wherein the first end is integral to the housing of the injection device. 15. An injection device comprising: a housing adapted to receive a syringe having a discharge nozzle, the syringe being moveable in the housing on actuation of the injection device along a longitudinal axis from a retracted position in which the discharge nozzle is contained within the housing and an extended position in which the discharge nozzle of the syringe extends from the housing through an exit aperture at a distal end of the device; a sliding component which extends, when in a first position, from the aperture, and is movable towards the housing into a second, retracted, position; and a guide for contacting an injection device with a user; the guide comprising: a first component including a first end adapted to engage the housing, the first component including at least one ratchet tooth, a second component including a second end adapted to engage a surface of the user's skin, wherein the second component is movable with respect to the first component, and wherein the second component includes an inner surface having a plurality of ratchet teeth disposed in series that engage the at least one ratchet tooth on the first component such that the housing moves towards the user's skin incrementally. 16. A device according to claim 15 , further comprising: an actuator; and a drive adapted to be acted upon by the actuator and in turn act upon the syringe to advance it from its retracted position to its extended position and discharge its contents through the discharge nozzle. 17. A device according to claim 15 , wherein the sliding component is part of a locking mechanism moveable from an engaged position, when the sliding component is in its first position, to a disengaged position, when the sliding component is in its second position, and adapted to prevent actuation of the device when it is in its engaged position and permit actuation of the device when it is in its disengaged position. 18. A kit according to any one of claims 9 to 11 or 12 to 14 or an injection device according to any one of claims 15 to 17 , wherein the injection device contains a substance selected from the group consisting of: golimumab, hormones, antitoxins, substances for the control of pain, substances for the control of thrombosis, substances for the control or elimination of infection, peptides, proteins, human insulin or a human insulin analogue or derivative, polysaccharide, DNA, RNA, enzymes, antibodies, oligonucleotide, antiallergics, antihistamines, anti-inflammatories, corticosteroids, disease modifying anti-rheumatic drugs, erythropoietin, or vaccines, for use in the treatment or prevention of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency, toxicity, pain, thrombosis, infection, diabetes mellitus, diabetic retinopathy, acute coronary syndrome, angina, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anaemia, or myelodysplasia, or in the expression of protective immunity. 19. A substance selected from the group consisting of: golimumab, hormones, antitoxins, substances for the control of pain, substances for the control of thrombosis, substances for the control or elimination of infection, peptides, proteins, human insulin or a human insulin analogue or derivative, polysaccharide, DNA, RNA, enzymes, antibodies, oligonucleotide, antiallergics, antihistamines, anti-inflammatories, corticosteroids, disease modifying anti-rheumatic drugs, erythropoietin, or vaccines, for use in the treatment or prevention of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency, toxicity, pain, thrombosis, infection, diabetes mellitus, diabetic retinopathy, acute coronary syndrome, angina, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anaemia, or myelodysplasia, or in the expression of protective immunity, by delivery of said substance to a human subject using a kit according to any one of claims 9 to 11 or 12 to 14 or an injection device according to any one of claims 15 to 17 . 20. An injection device for use in the treatment or prevention rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency, toxicity, pain, thrombosis, infection, diabetes mellitus, diabetic retinopathy, acute coronary syndrome, angina, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anaemia, or myelodysplasia, or in the expression of protective immunity, by delivery of a substance selected from the group consisting of: golimumab, hormones, antitoxins, substances for the control of pain, substances for the control of thrombosis, substances for the control or elimination of infection, peptides, proteins, human insulin or a human insulin analogue or derivative, polysaccharide, DNA, RNA, enzymes, antibodies, oligonucleotide, antiallergics, antihistamines, anti-inflammatories, corticosteroids, disease modifying anti-rheumatic drugs, erythropoietin, or vaccines, to a human subject by using the injection device, wherein the injection device is an injection device according to any one of claims 15 to 17 or is comprised in a kit according to any one of claims 9 to 11 or 12 to 14 .

Assignees

Inventors

Classifications

  • A61M5/2033Primary

    Spring-loaded one-shot injectors with or without automatic needle insertion (multishot dosing syringes A61M5/31525, needle insertion only A61M5/3287) · CPC title

  • Protruding skin to facilitate piercing, e.g. vacuum cylinders, vein immobilising means · CPC title

  • Having specific accessories · CPC title

  • Release is possible only when device is pushed against the skin, e.g. using a trigger which is blocked or inactive when the device is not pushed against the skin · CPC title

  • preventing premature release, e.g. by making use of a safety lock · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10709849B2 cover?
There is provided a guide 200 for contacting an injection device 110 with a user; the guide 200 having a first end 210 adapted to engage a housing 112 of the injection device 110 and a second end 220 adapted to engage the surface of a user's skin, wherein the guide 200 permits movement of the housing 112 towards the user's skin.
Who is the assignee on this patent?
Cilag Gmbh Int
What technology area does this patent fall under?
Primary CPC classification A61M5/2033. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 11 related publications on this page (citations in our corpus or others sharing the same primary CPC).